iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Pharmasset Phase 3 Plan Announced: Slides Presented This Morning on Pharmasset Conference Call
 
 
  Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes - (09/16/11)

Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C - shortened durations, monotherapy, INF-free - (10/10/11)

"the previously announced arm in HCV GT1 patients with a prior "null" response to an interferon (IFN) containing regimen, which was planned to assess PSI-7977/IFN/RBV, has been modified to an IFN-free 12-week regimen of PSI-7977/RBV"

EASL: PROTON Study: PSI-7977 QD with PEG/RBV: 12-week Safety, RVR, cEVR, & SVR12 in Treatment-naïve Patients with HCV GT2 or GT3 - (04/01/11)

EASL: ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCV RNA < LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) - (03/31/11)

EASL: PSI-7977 QD Plus PEG/RBV In HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study - (03/31/11) genotype 1

EASL: Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes - (03/31/11)

HCV1.gif

HCV2.gif

HCV3.gif

  
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org